Illumina, Inc. ILMN

ILMN Company Overview

Illumina, Inc. is a U.S.-based biotechnology company focused on genomic sequencing and array-based technologies used in research, clinical diagnostics, pharmaceutical development, and population genomics. The company operates primarily within the life sciences and molecular diagnostics industries and is widely recognized as a leading provider of next-generation sequencing (NGS) platforms. Illumina’s core revenue drivers include sequencing instruments, consumables, software, and services, with consumables representing a significant recurring revenue stream due to ongoing laboratory usage. Its products are used by academic institutions, clinical laboratories, pharmaceutical companies, biotechnology firms, and government research organizations.

Illumina was founded in 1998 and is headquartered in San Diego, California. The company evolved from a microarray technology provider into a dominant global sequencing company following the commercialization of high-throughput sequencing systems and several strategic acquisitions, including Solexa in 2007. Illumina’s competitive positioning has historically been supported by scale, extensive installed sequencing infrastructure, proprietary chemistry and bioinformatics capabilities, and long-term relationships with major genomic research centers and healthcare institutions.